ArticleFrontiers in cellular and infection microbiology2026
In-depth evaluation of false-positive biological reactions in the syphilis serological diagnosis: a cross-sectional study with two sampling components.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to systematically evaluate the disease spectrum, demographic characteristics, and autoantibody profiles associated with biological false-positive (BFP) reactions in serological tests for syphilis. Methods: A retrospective analysis was conducted on 87 patients with TRUST (+)/TPPA (-) results from January 2016 to February 2026 at West China Hospital, Sichuan University. Additionally, serum specimens from 1068 patients (including autoimmune diseases, Epstein-Barr virus infection, malignancy, and lupus anticoagulant positivity) were tested using chemiluminescence immunoassay and toluidine red unheated serum test (TRUST), and the autoantibody profiles of 539 of these patients were analyzed. Results: Among retrospective cases, unknown diseases accounted for the highest proportion (34.5%), followed by malignancy (12.6%) and neurological diseases (10.3%). In the cross-sectional case series, autoimmune diseases showed the highest BFP rate (52.3%), particularly rheumatoid arthritis (75.9%), connective tissue disease (62.4%), and Sjögren's syndrome (52.3%); the false-positive rate was 36.1% in patients with malignancy and 8.5% in patients with lupus anticoagulant positivity. BFP titers were predominantly low (1:1 or 1:2). EBV-positive BFP reactions occurred only in the 1-19 years age group with acute infection. Autoantibody profiling revealed that, among BFP patients with autoimmune diseases, those who were ANA-positive (n=235) exhibited substantially higher positivity rates for U1-snRNP (21.7%), Sm (9.4%), SS-A (60.9%), SS-B (36.6%), CENP B (14.0%), ANuA (24.3%), AHA (15.3%), and ARPA (11.9%), whereas ANA-negative patients (n=28) showed only low positivity for SS-A (25.0%) and Scl-70 (7.1%). Conclusion: BFP reactions are most common in autoimmune diseases, particularly SLE, SS, CTD, and RA, and typically present with low TRUST titers. ANA-positive BFP patients exhibit a broad autoantibody profile, while ANA-negative patients show limited positivity. Comprehensive clinical and autoantibody evaluation is essential to avoid misdiagnosis and unnecessary treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.